Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Breast Cancer Research : BCR|March 1, 2019
Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trialJoanne Mortimer, Jack Di Palma, Kendra Schmid, et al.
Wiley Interdisciplinary Reviews. Cognitive Science|July 8, 2015
Information structure: linguistic, cognitive, and processing approachesJennifer E Arnold, Elsi Kaiser, Jason M Kahn, et al.
Psychological Science|August 26, 2004
The old and thee, uh, new: disfluency and reference resolutionJennifer E Arnold, Michael K Tanenhaus, Rebecca J Altmann, et al.
Journal of Health and Social Behavior|October 28, 2006
The effects of governing board configuration on profound organizational change in hospitalsJeffrey A Alexander, Yining Ye, Shoou-Yih D Lee, et al.
Stroke|May 10, 2005
Recurrent stroke risk is higher than cardiac event risk after initial stroke/transient ischemic attackDevin L Brown, Lynda D Lisabeth, Canopy Roychoudhury, et al.
IEEE Transactions on Big Data|August 8, 2022
Country Image in COVID-19 Pandemic: A Case Study of ChinaHuimin Chen, Zeyu Zhu, Fanchao Qi, et al.
Journal of Substance Abuse Treatment|June 26, 2007
Do licensing and accreditation matter in outpatient substance abuse treatment programs?Rebecca Wells, Christy H Lemak, Jeffrey A Alexander, et al.
Journal of Oncology|May 12, 2011
Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancerHoward Burris, Joe Stephenson, Gregory A Otterson, et al.
Therapeutic Innovation & Regulatory Science|September 28, 2024
Experimental Study of the Promotional Implications of Proprietary Prescription Drug NamesSusana Peinado, Amie C O'Donoghue, Kevin R Betts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancerGeorge R Blumenschein, Karen Reckamp, G Joe Stephenson, et al.
Pageof 5